RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. A

Tweet Author

Tweet Content

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty

13 June 2025

Expanding the IL-17 Therapeutic Landscape

IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. Is there a need for more medications within the same therapeutic class?

13 June 2025

Social Determinants of Health in SLE

Social determinants of health (SDH), such as socioeconomic status and educational background are factors that are increasingly recognised as critical contributors to health outcomes in chronic diseases. Understanding how certain factors impact different RMDs is important, and new research into this for both systemic lupus erythematosus (SLE) and inflammatory arthritis was presented at the 2025 annual EULAR congress in Barcelona.

13 June 2025

Safety of Recombinant Zoster Vaccine in Rheumatic Patients

New work presented at the 2025 annual EULAR congress in Barcelona focuses on the recombinant zoster vaccine (RZV), which contains recombinant glycoprotein E – the major target of CD4+T-cells. The abstract describes the tolerability and safety of RZV in patients with inflammatory rheumatic and musculoskeletal diseases (iRMD), showcasing interim data from an ongoing study.

Diagnostic delay in #SpA 🔹️Data from the @Official_ASAS Study 🔹️4339 patients 🔹️Delay was 6.6 years 🔹

Tweet Author

Nellziade

Tweet Content

Diagnostic delay in #SpA 🔹️Data from the @Official_ASAS Study 🔹️4339 patients 🔹️Delay was 6.6 years 🔹️Longer in axSpA and IBD-SpA, shorter in PsA and pSpA 🔹️Associated with type of initial symptoms (shorter in peripheral) POS0909 #EULAR2025 @rheumnow https://t.co/3BMYFxbKiq

Links

https://x.com/Nellziade/status/1933284700258283807/photo/1

LDCT to assess disease progression in early axSpA: -Data from SPACE cohort 67 pts (>50% male,>80% hLAB27+) - LD

Tweet Author

AdelaCastro222

Tweet Content

LDCT to assess disease progression in early axSpA: -Data from SPACE cohort 67 pts (>50% male,>80% hLAB27+) - LDCT at baseline and 2 years apart. -Overall 22% pt with net disease progression. -Spine progression most frequent on thoracic spine. -Good reliability in assessing https://t.co/M2jkDusD41

Links

https://x.com/AdelaCastro222/status/1933456614893265141/photo/1

🎯 Early MTX hits the mark — but only in ACPA-negative. In TREAT EARLIER, 1 year of MTX led to lasting benefits at 5

Tweet Author

JihaRheum

Tweet Content

🎯 Early MTX hits the mark — but only in ACPA-negative. In TREAT EARLIER, 1 year of MTX led to lasting benefits at 5 years: ➖ Less RA ➖ Better function ❌ No benefit in ACPA+ Abstract#OP0324 @RheumNow #EULAR2025

#ANCA #vasculitis is not created equally REVEAL cohort 588 ANCA Initial & 12 months #BVAS (activity index) mean ?

Tweet Author

Janetbirdope

Tweet Content

#ANCA #vasculitis is not created equally REVEAL cohort 588 ANCA Initial & 12 months #BVAS (activity index) mean ⬇️BVAS over 1 yr in all groups #GPA #MPA #eGPA 5yr survival not = over time ⬆️survival in eGPA & GPA vs MPA #POS0329 #EULAR2025 @RheumNow @eular_org https://t.co/cUKytqNZnS

Links

https://x.com/Janetbirdope/status/1933448768034148386/photo/1

#EULAR2025 Abstr#POS0325 Immunosuppressant-free is not only confined to CAR-T. Our cohort study in #SLE: 20% patients we

Tweet Author

Yuz6Yusof

Tweet Content

#EULAR2025 Abstr#POS0325 Immunosuppressant-free is not only confined to CAR-T. Our cohort study in #SLE: 20% patients were “Super-Responder” (>3yrs response) inc. 7% IS-free after one Rituximab cycle. Non-European, APS & shorter disease duration predicted super-response @RheumNow https://t.co/nPIYpGoynR

Links

https://x.com/Yuz6Yusof/status/1933456042710401484/photo/1

Is RA just one disease? No, & increasingly more efforts to subgroup RA on diff levels Simple approach - derived ph

Tweet Author

drdavidliew

Tweet Content

Is RA just one disease? No, & increasingly more efforts to subgroup RA on diff levels Simple approach - derived phenotypes map (independent of ACPA): - to broad histopath - to MTX response Omics is good, but still need to do the simple stuff better! #EULAR2025 OP0328 @RheumNow https://t.co/a8Vl7Kcjso

Links

https://x.com/drdavidliew/status/1933460967989628949/photo/1

Topics

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. A

Diagnostic delay in #SpA 🔹️Data from the @Official_ASAS Study 🔹️4339 patients 🔹️Delay was 6.6 years 🔹

LDCT to assess disease progression in early axSpA: -Data from SPACE cohort 67 pts (>50% male,>80% hLAB27+) - LD

🎯 Early MTX hits the mark — but only in ACPA-negative. In TREAT EARLIER, 1 year of MTX led to lasting benefits at 5

#ANCA #vasculitis is not created equally REVEAL cohort 588 ANCA Initial & 12 months #BVAS (activity index) mean ?

#EULAR2025 Abstr#POS0325 Immunosuppressant-free is not only confined to CAR-T. Our cohort study in #SLE: 20% patients we

Is RA just one disease? No, & increasingly more efforts to subgroup RA on diff levels Simple approach - derived ph

Do you get our email newsletter?